Polar NanoPharma, Collaborators and Members of Cambra de Tarragona
Polar NanoPharma has been awarded the Second National Prize of the Impulsa Startup programme, promoted by the Cámara de Comercio de España, following its selection as regional winner by the Cambra de Tarragona.
The national final took place during 4YFN 2026 in Barcelona, one of Europe’s leading innovation and entrepreneurship platforms, bringing together the top startups from across Spain selected by the national network of Chambers of Commerce.
This recognition highlights the technological strength and market potential of Polar NanoPharma’s proprietary oncology nanomedicine platform based on advanced polymeric encapsulation systems, designed to improve the safety and efficacy profile of anticancer therapies.
A milestone in national visibility
Receiving the Second National Prize reinforces:
- Institutional validation of Polar NanoPharma’s deep-tech innovation
- National visibility among investors, industry stakeholders and innovation ecosystems
- Strategic positioning within the Spanish biotech and nanomedicine landscape
The Impulsa Startup programme aims to accelerate high-potential entrepreneurial projects through mentoring, business development support and national exposure. Competing at national level confirms the maturity and scalability of Polar NanoPharma’s technology and business model.
Commitment to safer oncology solutions
Polar NanoPharma remains committed to advancing its encapsulation platform toward clinical development, strategic partnerships and long-term value creation.
This award strengthens the company’s mission to translate scientific innovation into safer and more effective therapeutic solutions for cancer patients, combining rigorous research with strategic execution.
The company acknowledges the continued support of the Cámara de Comercio de España and the Cambra de Tarragona, as well as the dedication of its scientific team and collaborators.
Polar NanoPharma continues to move forward with determination, responsibility and a clear vision: redefining drug delivery in oncology through advanced nanomedicine.
Congrats to the winner: Limbium Makers
Polar NanoPharma has been awarded First Prize at the Phase II Demo Day of the Impulsa Startup programme, organised by the Cambra de Tarragona and co-funded by the European Next Generation Funds.
The award, endowed with €4,800, recognises the technological strength, maturity and impact potential of Polar NanoPharma’s oncology nanomedicine platform based on advanced polymeric encapsulation systems, designed to improve the safety and efficacy of cancer therapies.
The Demo Day brought together 15 high-potential startups across diverse sectors, including health, education, ecology, tourism, wellness, architecture and technology. The event has established itself as a key platform for fostering regional entrepreneurial growth and innovation. Congrats to all the participants and specially Josep with Inroom, great project also incubated by EAE Business School.
Selection for the national final
Following this achievement, Polar NanoPharma has also been selected to represent Tarragona at the national final of the Impulsa Startup programme, where top startups from across Spain will compete on a national stage during 4YFN (MWC) 2026, one of Europe’s leading innovation platforms.
Advancing to the national stage reinforces:
- Institutional validation of the company’s proprietary drug delivery technology
- Its positioning as a high-impact deep-tech biotech startup
- Increased national visibility among investors, corporations and innovation stakeholders
Participation in the national final represents an important strategic milestone as Polar NanoPharma continues to translate scientific innovation into clinically relevant solutions in oncology.
The company acknowledges the continued support and strategic guidance provided by the Cambra de Tarragona throughout the programme.
Polar NanoPharma remains focused on advancing its encapsulation platform toward clinical development, strategic partnerships and long-term value creation in the field of nanomedicine.
Polar NanoPharma has been selected among the 6 winning projects of the Programa Primer, following its participation in the Demo Day held at the Estrella Damm Factory in Barcelona.
The Demo Day marked the conclusion of the Healthcare Vallès acceleration program, promoted by CECOT and co-funded by the Government of Catalonia (Generalitat de Catalunya). During the event, 20 high-potential innovation-driven projects from across Catalonia presented their business and technology strategies to a panel of experts, investors, and ecosystem stakeholders.
Being selected among the top 6 projects provides Polar NanoPharma with access to 4YFN (Four Years From Now), one of the most relevant international startup and innovation platforms within the Mobile World Congress (MWC). This opportunity significantly strengthens the company’s international visibility, investor exposure, and strategic partnering potential.
Polar NanoPharma is developing a proprietary nanomedicine platform based on advanced drug encapsulation and controlled release systems, designed to improve the efficacy, safety, and therapeutic index of cancer treatments. The selection by Programa Primer validates not only the scientific maturity of the technology, but also its business potential, scalability, and alignment with unmet medical needs in oncology.
The recognition further supports the company’s growth strategy, focused on technology validation, strategic partnerships, and future clinical development, while positioning Polar NanoPharma as a high-potential biotech startup within the European healthcare innovation ecosystem.
Polar NanoPharma would like to thank the Healthcare Vallès program at CECOT for the mentorship, strategic guidance, and continuous support provided throughout the acceleration process, and to congratulate all participating projects for the strong quality and ambition demonstrated.
This milestone represents a key step in Polar NanoPharma’s roadmap toward international expansion, investor engagement, and long-term value creation in oncology drug development.
Polar NanoPharma took part in the Catalan Pitch Competition 2025, organized by ACCIÓ within the framework of Tech Spirit Barcelona, one of the leading innovation events in Catalonia. The competition, held at the emblematic Casa Llotja de Mar, brought together some of the country’s most promising start-ups in biotechnology, deep tech, and disruptive technologies.
We are pleased to announce that Polar NanoPharma successfully passed the first selection round, a milestone that reflects the scientific strength of our nanomedicine platform and the dedication of our entire team. The competition showcased an exceptional level of quality, with projects demonstrating significant potential impact across sectors such as healthcare, energy, artificial intelligence, and advanced materials.
Participating in this initiative has been a unique opportunity to increase visibility for our Ecostratar Technology, present our vision to international investors and experts, and connect with an ecosystem that actively drives deep innovation. This experience reinforces our conviction that nanomedicines has a key role to play in the future of cancer treatment.
Access to the catalog of all the participating start ups HERE
We extend our congratulations to ShinePhi, winner of the Catalan Start-up of the Year Award 2025, for their outstanding trajectory and technological proposal.
At Polar NanoPharma, we remain committed to advancing safer and more effective solutions for cancer patients, and we thank ACCIÓ, Tech Barcelona, EAE Business School and the entire organization for the opportunity to be part of this edition.
Polar NanoPharma has been selected to participate in Phase 2 (Despega) of the Impulsa Startup programme, an initiative promoted by the Tarragona Chamber of Commerce and co-funded by the European Social Fund Plus (ESF+) under the 2021–2027 European framework.
The Impulsa Startup programme aims to accelerate innovative, high-growth entrepreneurial projects, providing strategic support, specialised training and expert mentoring. Phase 2 is designed for startups with a validated Minimum Viable Product (MVP) seeking to strengthen their business model and prepare for scale-up.
Polar NanoPharma’s selection highlights the technological maturity and disruptive potential of its oncology nanomedicine platform based on advanced polymeric encapsulation systems, focused on improving the efficacy and safety of cancer therapies.
Participation in this phase will enable the company to further strengthen its business strategy, market positioning and development roadmap, within a competitive, deep-tech–driven innovation ecosystem aligned with European standards.
Polar NanoPharma thanks the Tarragona Chamber of Commerce for its trust and continued commitment to supporting high-impact technological entrepreneurship.
More information about the Impulsa Startup programme:
https://www.camara.es/creacion-de-empresas/programa-impulsa-startup
Pictures source: Iván Ramos, Josep Rocas
Yesterday we had the honor of presenting Polar NanoPharma at the 3rd edition of the EconomistesBAN Investment Forum in Tarragona, which also marked the 75th edition of this leading platform connecting startups and investors.
Organized by the Col·legi d’Economistes de Catalunya, the event took place at the historic Palau de la Diputació Provincial de Tarragona, with institutional representation from Promoció Econòmica i d’Ocupació de Tarragona, Cambra de Comerç de Reus, Universitat Rovira i Virgili, and ACCIÓ.
We have the chance to explain our project to accelerate the development of our polymer-based drug delivery platform for oncology. Ecostratar is a technology designed to make cancer therapies safer, more efficient, and more patient-centered.
Big thanks to the organizers for supporting purpose-driven innovation.
We remain committed to building a future where nanomedicine improves lives.
#PolarNanoPharma #EconomistesBAN #75Edition #HealthStartups #Nanomedicine #TechTransfer #OncologyInnovation #ImpactInvestment
We’re proud to announce that Polar NanoPharma has been selected as one of the 7 startups to join the prestigious EAE Emprende acceleration program, following a high-impact Demo Day held at Tech Barcelona – Pier01.
Out of 17 cutting-edge startups, our mission to revolutionize cancer treatment through nanomedicine was recognized by a panel of leading experts and investors:
🔹 Daniel de Yzaguirre – Senior Financial Advisor at ACCIÓ
🔹 Eugeni Escrig – Business Angel
🔹 Gerard Forca – Tech Barcelona
🔹 Borja Rosell – Founder of Akiles and Verse
Thanks Patricia Muñido for the organization
👉 See the official EAE Emprende post on Instagram
Pictures source: Instagram EAEbarcelona_BS
What does this mean for Polar NanoPharma?
We’ve earned a place in the EAE acceleration program designed to scale high-potential startups. During this journey, we will gain:
✅ Top-tier mentorship
✅ Access to investors and funding opportunities
✅ Tailored training and business strategy
✅ A powerful innovation network of founders, experts, and institutions
✅ Co-working Space at the Pier 01.
Hosted by the EAE Business School Barcelona, the program is a launchpad for visionary startups ready to transform their industries.
Our Purpose: Redefining Cancer Therapy with Nanotechnology
At Polar NanoPharma, we engineer next-generation polymer-based nanoparticle systems for controlled drug delivery in oncology. Our Ecostratar technology aims to reduce systemic toxicity, enhance drug efficacy, and increase patient safety.
🧬 We are committed to reshaping the future of cancer treatment – and this milestone brings us one step closer.
Thank You, EAE Emprende 🙌
Thank you for believing in deep science, real-world impact, and disruptive innovation.
And congratulations to the Demo Day winner: @beloo.app, the first app to improve cyclist safety in real time. 🏆
📍 Polar NanoPharma Official Website
💼 LinkedIn
🧪 Discover Our Technology
This is just the beginning.
From Barcelona to the world, we keep pushing the boundaries of science to deliver hope, precision, and better outcomes in cancer care.
#EAEEmprende #PolarNanoPharma #BiotechInnovation #Startups #Nanomedicine #DemoDayEAE #TechBarcelona #HealthTech #StartupAcceleration #DeepTechForGood #ScienceForImpact #EAEAlumni #ACCIÓ #StartupBarcelona #ImpactStartups #LifeSciences #entrepreneurs
We’re proud to share that Polar NanoPharma had the honor of presenting at the 8th China (Shenzhen) Innovation & Entrepreneurship International Competition (IEIC) – Spain Division, held on October 14th. Competing among 276 applicants from diverse industries, we were enthusiastic to be shortlisted as one of the top 3 teams in our category.
Facing strong competitors from across Spain, the experience of showcasing our breakthrough nanoparticle-based cancer therapies on such a prestigious international stage was invaluable. This opportunity allowed us to connect with China’s extensive innovation ecosystem, gain valuable insights, and reinforce our commitment to advancing oncology care.
Thank you to Shenzhen’s Barcelona division for this incredible opportunity and to everyone who supported us on this journey. This milestone has only strengthened our determination, and we look forward to sharing more updates as we continue driving Polar NanoPharma’s mission forward!
🌐 Polar NanoPharma’s New Website is Live! 🚀
We’re excited to announce the official launch of Polar NanoPharma’s new website! 🎉
Improving drugs solubility, boosting circulation time, and ensuring targeted and controlled release, we’re working to make cancer treatment safer and more effective for patients.
How do you see nanotechnology and non-viral carriers, impacting healthcare in the next few years? Let’s connect and talk about it! 📩
#Nanotechnology #Oncology #DrugDelivery #Innovation #Polycarbamate #Polyurea #FutureOfMedicine